You are here

  • Home
  • Archive
  • Volume 7, Issue 1
  • Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

Article info

Article menu

Download PDFPDF

XML
Research Article
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma

Authors

  • Arun Rajan Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health 10-CRC, Room 4-5330, 10 Center Drive 20892 Bethesda MD USA PubMed articlesGoogle scholar articles
  • Christopher R. Heery Laboratory of Tumor Immunology and Biology, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Anish Thomas Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health 10-CRC, Room 4-5330, 10 Center Drive 20892 Bethesda MD USA PubMed articlesGoogle scholar articles
  • Andrew L. Mammen Laboratory of Muscle Stem Cells and Gene RegulationNational Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Susan Perry Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health 10-CRC, Room 4-5330, 10 Center Drive 20892 Bethesda MD USA PubMed articlesGoogle scholar articles
  • Geraldine O’Sullivan Coyne Genitourinary Malignancies Branch, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health 10 Center Dr., 13N240 20892 Bethesda MD USA PubMed articlesGoogle scholar articles
  • Udayan Guha Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health 10-CRC, Room 4-5330, 10 Center Drive 20892 Bethesda MD USA PubMed articlesGoogle scholar articles
  • Arlene Berman Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health 10-CRC, Room 4-5330, 10 Center Drive 20892 Bethesda MD USA PubMed articlesGoogle scholar articles
  • Eva Szabo Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health 10-CRC, Room 4-5330, 10 Center Drive 20892 Bethesda MD USA Lung and Upper Aerodigestive Cancer Research Group, Division of Cancer PreventionNational Cancer Institute, National Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Ravi A. Madan Genitourinary Malignancies Branch, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health 10 Center Dr., 13N240 20892 Bethesda MD USA PubMed articlesGoogle scholar articles
  • Leomar Y. Ballester Laboratory of Pathology, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Stefania Pittaluga Laboratory of Pathology, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Renee N. Donahue Laboratory of Tumor Immunology and Biology, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Yo-Ting Tsai Laboratory of Tumor Immunology and Biology, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Lauren M. Lepone Laboratory of Tumor Immunology and Biology, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Kevin Chin EMD Serono Billerica MA USA PubMed articlesGoogle scholar articles
  • Fiona Ginty GE Global Research Center Niskayuna NY USA PubMed articlesGoogle scholar articles
  • Anup Sood GE Global Research Center Niskayuna NY USA PubMed articlesGoogle scholar articles
  • Stephen M. Hewitt Laboratory of Pathology, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Jeffrey Schlom Laboratory of Tumor Immunology and Biology, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health Bethesda MD USA PubMed articlesGoogle scholar articles
  • Raffit Hassan Thoracic and Gastrointestinal Malignancies Branch, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health 10-CRC, Room 4-5330, 10 Center Drive 20892 Bethesda MD USA PubMed articlesGoogle scholar articles
  • James L. Gulley Genitourinary Malignancies Branch, Center for Cancer ResearchNational Cancer Institute, National Institutes of Health 10 Center Dr., 13N240 20892 Bethesda MD USA PubMed articlesGoogle scholar articles
  1. ↵a 240.760.6236 rajana{at}mail.nih.gov
  2. ↵b chris.heery{at}gmail.com
  3. ↵c anish.thomas{at}nih.gov
  4. ↵d andrew.mammen{at}nih.gov
  5. ↵e susan.perry{at}nih.gov
  6. ↵f geraldine.osullivancoyne{at}nih.gov
  7. ↵g udayan.guha{at}nih.gov
  8. ↵h arleneb{at}mail.nih.gov
  9. ↵i szaboe{at}mail.nih.gov
  10. ↵j madanr{at}mail.nih.gov
  11. ↵k Leomar.Y.Ballester{at}uth.tmc.edu
  12. ↵l stefpitt{at}mail.nih.gov
  13. ↵m renee.donahue{at}nih.gov
  14. ↵n yo-ting.tsai{at}nih.gov
  15. ↵o lmlepone{at}gmail.com
  16. ↵p kevin.chin{at}emdserono.com
  17. ↵q ginty{at}research.ge.com
  18. ↵r Anup.Sood{at}ge.com
  19. ↵s hewitts{at}mail.nih.gov
  20. ↵t schlomj{at}mail.nih.gov
  21. ↵u hassanr{at}mail.nih.gov
  22. ↵v 301-480-8870 gulleyj{at}mail.nih.gov
View Full Text

Citation

Rajan A, Heery CR, Thomas A, et al
Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma
Journal for ImmunoTherapy of Cancer 2019;7:269. doi: 10.1186/s40425-019-0723-9

Publication history

  • Received May 16, 2019
  • Accepted August 28, 2019
  • First published October 21, 2019.
Online issue publication 
January 08, 2022

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© The Author(s). Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.